A new flu vaccine developed by Moderna, utilising the same mRNA technology that played a pivotal role in the global response to the COVID-19 pandemic, is currently under review by US health advisers. The Food and Drug Administration (FDA) advisory committee is debating the approval of Moderna's mFlusvia, which the company hopes will be an option for individuals aged 50 and older. This meeting represents a crucial step towards a final decision before the upcoming winter flu season in the United States.
The potential introduction of an mRNA-based flu vaccine marks a significant advancement in vaccine technology. Existing flu vaccines are manufactured using various methods, some of which are more time-consuming. Experts suggest that the speed of mRNA vaccine production could be particularly beneficial in situations where the influenza virus mutates unexpectedly, necessitating the rapid development of new vaccine doses to match the evolving strains. This could offer greater flexibility and responsiveness in public health efforts against seasonal influenza, which causes tens of thousands of deaths annually in the US, with older adults being particularly vulnerable.
Moderna's application is supported by data from a study involving 40,000 participants aged 50 and over. This research indicated that mFlusvia reduced the incidence of flu cases by approximately 27% when compared to another commonly used vaccine brand. Ahead of the advisory committee meeting, the FDA published a favourable review of this data, reporting no significant safety concerns. Moderna is seeking full approval for the vaccine's use in the 50- to 64-year-old demographic, alongside authorisation for use in those aged 65 and older while further testing is conducted.
The journey to this stage has not been without its challenges. Earlier this year, Moderna's data was at the centre of a public disagreement when a former top FDA official initially blocked the company's application. The official contended that the vaccine should have been compared against a high-dose flu vaccine, typically recommended for seniors, rather than a standard-dose brand. Moderna challenged this decision, highlighting that FDA staff had previously approved the main study's design and referencing a separate, smaller study that compared the mRNA shot with a high-dose vaccine for seniors. Following this dispute, the FDA subsequently accepted Moderna's application.
The expert panel will also evaluate the findings of that smaller study, which indicated that Moderna's shot generated flu-fighting antibodies at levels similar to a high-dose senior vaccine. However, the FDA's initial review also noted that the new vaccine currently lacks data specifically on very frail older adults and individuals with compromised immune systems. This ongoing scrutiny highlights the rigorous process involved in evaluating new vaccine technologies for widespread public use.
The development of an mRNA flu vaccine holds considerable implications for global public health strategies, including those in the UK. While this approval process is taking place in the US, successful authorisation could pave the way for similar vaccines to be considered by regulatory bodies like the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK in the future. The potential benefits of faster manufacturing and adaptability to new flu strains could enhance the UK's annual flu vaccination programme, which is crucial for protecting vulnerable populations and reducing pressure on the NHS during winter months. According to NHS data, hundreds of thousands of people in England are hospitalised with flu or flu-like illnesses each year, underscoring the ongoing need for effective vaccination strategies.
Source: US Food and Drug Administration (FDA), Moderna